12 Series B Biotech Investors — 12 Currently Deploying

Investing in entrepreneurs building infrastructure and value chains around data, from the full data stack (infrastructure to applications) with belief that accurate, actionable dat…

Partner with visionary founders at the intersection of bold vision and relentless execution. Active investors seeking to be partners during the rapid growth stage of scaling journe…

Founder-driven investing focused on bold teams and transformative ideas. Hands-on approach informed by past lives as founders and operators.

Correlation Ventures backs groundbreaking technology and data science companies that solve industry problems through rapid decision-making and industry-leading networks.

Speedinvest provides European startups with 'more expertise, connections, reach, and momentum' through specialist investment teams across six core sectors, backing companies from s…

Support domestic and international startups through capital provision and business collaboration, leveraging Dentsu Group's creative and strategic resources alongside global VC net…

Early-stage venture firm investing in technical founders solving hard engineering and science problems through the 'Super Evolution' — a non-linear approach to innovation enabled b…

Early-stage tech investments in the US and Israel, providing access and meaningful connections to help brilliant minds breakthrough.

Multi-stage venture capital firm that goes beyond traditional VC playbook by providing entrepreneurs support of a global ecosystem, connecting innovators everywhere.

Supporting ambitious founders to build category defining companies

Blue Ivy Ventures provides Yale alumni accredited investors access to diversified venture capital investments co-invested alongside leading VC firms, combining a curated annual fun…

How many series b biotech investors are actively deploying right now?

DryPowder tracks 12 series b biotech funds. Of these, 12 are currently deploying capital based on recent fund closes, portfolio activity, and partner signals. Use DryPowder's fund matching to see which ones fit your specific startup.

What check size do series b biotech VCs write?

Among 12 series b biotech funds on DryPowder, check sizes run from $250K–$3M. Ranges vary by fund size, vintage, and whether the fund leads rounds. Each fund profile shows check size detail and lead preference.

How do I get a meeting with a series b biotech VC?

A warm intro is still the fastest path. Most series b biotech VCs on DryPowder do accept cold outreach or direct applications, but response rates vary widely by fund. Before reaching out, use DryPowder's AI matching to get a fit score and specific talking points. Founders who lead with thesis-aligned framing get significantly better response rates than those sending the same deck to every fund on a list.

How long does a Series B process take, and how is it different from Series A?

Series B processes typically run 3-6 months and are significantly more diligence-intensive than Series A. Investors will conduct deep cohort analysis, churn reviews, and GTM efficiency audits. Most Series B investors want to lead or co-lead, so you are running a smaller, more targeted process than at earlier stages. Financial modeling and competitive positioning matter as much as the founding narrative at this point.

How many series b biotech investors should I be talking to at once?

Most fundraisers recommend a parallel process: identify 20-40 target investors but approach your highest-fit funds first. Of the 12 series b biotech funds currently deploying, not all will match your specific stage and sector. Use fund matching to find your top 10-15, approach those first, collect feedback, then go wider. Going to every fund simultaneously without qualifying first burns bridges and dilutes the urgency that helps close a round.

How is DryPowder different from building a VC list on LinkedIn or Crunchbase?

The fund list you build on LinkedIn or Crunchbase is roughly the same list every other founder is building. DryPowder adds three things a manual search cannot: deployment signals (which funds have recently closed new vehicles and are actively writing checks), AI thesis matching (which of the 12 series b biotech funds actually fits your specific startup, ranked by fit), and verified partner contact details. The goal is 15 targeted, thesis-aligned pitches instead of 150 generic ones.